Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAPENTADOL vs HYDROCODONE BITARTRATE AND ACETAMINOPHEN
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Tapentadol is a centrally acting analgesic with a dual mechanism of action: mu-opioid receptor agonist and norepinephrine reuptake inhibitor.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Management of moderate to severe acute pain,Management of neuropathic pain associated with diabetic peripheral neuropathy,Management of chronic pain
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.
Immediate-release tablets: 50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg per day. Extended-release tablets: 50-250 mg orally twice daily (every 12 hours); maximum 500 mg per day.
Oral: 1-2 tablets (5-10 mg hydrocodone/325-650 mg acetaminophen) every 4-6 hours as needed for pain; maximum daily doses: hydrocodone 40 mg, acetaminophen 3000 mg.
Terminal elimination half-life is approximately 4 hours (range 3-5 hours) for immediate-release; for extended-release, effective half-life is about 4-6 hours due to prolonged absorption.
Hydrocodone: 3.8-7.4 hours (terminal), prolonged in hepatic impairment. Acetaminophen: 1.5-2.5 hours (terminal).
Creatinine clearance (Cr Cl) 30-80 m L/min: No adjustment needed. Cr Cl <30 m L/min: Not recommended (extended-release) or use with caution and reduce dose by 50% (immediate-release). Hemodialysis: Not recommended.
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use or reduce dose and frequency. Hemodialysis: Not recommended.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and interactions with drugs affecting cytochrome P450 isoenzymes.
First trimester: Limited data, no clear evidence of major malformations in humans, but opioid use associated with neural tube defects in some studies. Second and third trimesters: Chronic use may lead to fetal opioid dependence and neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use near term due to risk of respiratory depression at birth.
First trimester: Limited human data; animal studies show no consistent teratogenicity. Second and third trimesters: Chronic use may cause fetal opioid dependence, neonatal withdrawal syndrome, and reduced fetal growth. Acetaminophen component: no known teratogenic risk at therapeutic doses.
Tapentadol is a dual-mechanism opioid agonist and norepinephrine reuptake inhibitor. It has a lower incidence of opioid-induced nausea and vomiting compared to morphine. Avoid use in patients with severe hepatic impairment. Maximum daily dose is 600 mg. Do not crush extended-release tablets. Discontinuation should be gradual to avoid withdrawal. Serotonin syndrome risk when combined with serotonergic agents.
Hydrocodone/acetaminophen carries a boxed warning for addiction, abuse, and misuse; respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; and hepatotoxicity (acetaminophen). Avoid in patients with severe respiratory depression, acute or severe bronchial asthma, GI obstruction, or known acetaminophen hypersensitivity. Maximum acetaminophen dose from all sources should not exceed 4 g/day (3 g/day in at-risk patients). Use with caution in elderly, cachectic, or debilitated patients due to increased risk of respiratory depression. CYP3A4 inducers (e.g., rifampin) may reduce hydrocodone efficacy; CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity. Do not combine with other CNS depressants without dose adjustment. Monitor for signs of opioid-induced constipation; prescribe a bowel regimen. Prescribe immediate-release formulations only for acute pain (generally ≤3 days). Avoid combining with MAOIs or within 14 days of MAOI use.
"Flunarizine, a calcium channel blocker with antihistaminergic and antidopaminergic properties, can potentiate the central nervous system (CNS) depressant effects of tapentadol, a mu-opioid receptor agonist and norepinephrine reuptake inhibitor. This additive pharmacodynamic interaction may lead to excessive sedation, respiratory depression, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents. Clinically, patients may experience profound drowsiness, confusion, and potentially life-threatening respiratory compromise, particularly during initiation or dose escalation of either agent."
"Concomitant use of quetiapine and tapentadol may result in additive central nervous system (CNS) depression, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Quetiapine, an atypical antipsychotic with antagonist activity at multiple receptors including histamine H1 and alpha1-adrenergic receptors, contributes to sedation and hypotension. Tapentadol, a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, also causes CNS depression. The combination increases the risk of profound sedation, respiratory compromise, coma, and death, particularly in elderly or debilitated patients."
"Tapentadol, a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, and dronabinol, a cannabinoid receptor agonist, both produce central nervous system (CNS) depression. Concurrent use leads to additive or synergistic sedative and respiratory depressant effects, increasing the risk of excessive sedation, respiratory depression, coma, and death. Patients should be monitored closely for signs of CNS depression, especially during initiation or dose adjustment of either drug."
No interactions on record
TAPENTADOL and HYDROCODONE BITARTRATE AND ACETAMINOPHEN are distinct pharmacological agents. TAPENTADOL belongs to the Opioid Agonist class and is primarily used for Management of moderate to severe acute painManagement of neuropathic pain associated with diabetic peripheral neuropathyManagement of chronic pain. HYDROCODONE BITARTRATE AND ACETAMINOPHEN belongs to the Opioid Agonist class and is primarily used for Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate.. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. TAPENTADOL carries a safety status of Category A/B, whereas HYDROCODONE BITARTRATE AND ACETAMINOPHEN safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Extensively metabolized via conjugation (primarily glucuronidation) and by CYP2C9 and CYP2C19 to a minor extent. Major metabolites are inactive.
Hydrocodone: primarily CYP3A4 and CYP2D6 to hydromorphone (active). Acetaminophen: primarily glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation to NAPQI (toxic).
Primarily renal: approximately 95% of the dose is excreted in urine (60% as tapentadol glucuronide, 15% as unchanged tapentadol, and 20% as other metabolites); less than 3% excreted in feces.
Renal excretion of metabolites (hydrocodone: ~60% as conjugates, <12% unchanged; acetaminophen: ~85-90% as glucuronide and sulfate conjugates, <5% unchanged). Biliary/fecal elimination of minor metabolites.
Approximately 20% bound to plasma proteins (primarily albumin).
Hydrocodone: ~20-50% bound to albumin and other proteins. Acetaminophen: 10-25% bound to albumin.
540 L (approximately 7.7 L/kg for a 70 kg adult), indicating extensive tissue distribution.
Hydrocodone: 3.3-4.7 L/kg (extensive tissue distribution). Acetaminophen: 0.75-1.0 L/kg (primarily total body water).
Oral: approximately 32% due to first-pass metabolism; intravenous: 100%.
Oral: Hydrocodone ~70-80% (first-pass metabolism). Acetaminophen ~60-90% (product dependent).
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and increase dosing interval to every 8 hours (immediate-release) or every 12 hours (extended-release). Child-Pugh Class C: Contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce total daily dose by 50% or extend dosing interval. Child-Pugh C: Avoid use.
Safety and efficacy not established in children <18 years; not recommended.
Not recommended for children <18 years due to safety concerns. For postoperative tonsillectomy/adenoidectomy: contraindicated.
Start at low end of dosing range; monitor for CNS effects, constipation, and respiratory depression. Immediate-release: 50 mg every 6 hours initially; extended-release: not recommended for opioid-naïve elderly.
Initiate at lowest effective dose (e.g., 2.5 mg hydrocodone/325 mg acetaminophen) and titrate slowly; monitor for CNS depression and constipation. Avoid in renal impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen overdose.
Addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; seizures; risk of serotonin syndrome; adrenal insufficiency; and withdrawal.
Respiratory depression, drug dependence, abuse potential, risks with CNS depressants, elderly/debilitated patients, hepatic impairment, renal impairment, severe hypotension, head injury, seizures, use in pregnancy, use in breastfeeding, adrenal insufficiency, anaphylaxis, withdrawal, and driving impairment.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days; hypersensitivity to tapentadol.
Significant respiratory depression, acute or severe bronchial asthma, GI obstruction (including paralytic ileus), hypersensitivity to hydrocodone or acetaminophen, severe hepatic impairment, and known or suspected gastrointestinal obstruction.
No specific food interactions. Alcohol should be avoided due to additive CNS depressant effects.
Avoid alcohol consumption due to increased risk of hepatotoxicity and additive CNS depression. Grapefruit juice may inhibit CYP3A4 and potentially increase hydrocodone levels; consider avoiding or limiting intake. No significant food restrictions otherwise; may take with or without food. Maintain adequate hydration to prevent constipation.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.8). Infant exposure is low but may cause sedation or respiratory depression in neonates, especially with high maternal doses or prolonged use. Caution advised; monitor infant for signs of sedation or poor feeding.
Hydrocodone is excreted into human breast milk, with an M/P ratio approximately 2.5. Postpartum use may lead to infant sedation and respiratory depression, especially in CYP2D6 ultra-rapid metabolizers. Acetaminophen is excreted in low levels. Use is generally avoided due to risks; if used, monitor infant for drowsiness and feeding difficulties.
No specific dose adjustments recommended, but pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may require higher doses to maintain analgesia. Use lowest effective dose for shortest duration. Avoid chronic use; consider opioid-sparing strategies.
No dosing adjustment recommended specifically for pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may result in lower serum concentrations; however, due to fetal risks, use the lowest effective dose for the shortest duration. Avoid use in third trimester unless necessary; monitor for neonatal withdrawal.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve tablets; swallow whole.,Avoid alcohol and other CNS depressants (e.g., sedatives, tranquilizers) as they may increase risk of serious side effects like respiratory depression.,Dizziness or drowsiness may occur; avoid driving or operating machinery until you know how the medication affects you.,Do not stop abruptly; taper dose under medical supervision to prevent withdrawal symptoms.,Common side effects include nausea, vomiting, constipation, dizziness, and headache.,Report symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heartbeat, fever, muscle stiffness) immediately.,Keep out of reach of children; misuse can cause overdose and death.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and any products containing acetaminophen (e.g., Tylenol, cold medicines) to prevent liver damage.,Do not drive or operate heavy machinery until you know how this medication affects you.,Store in a secure place away from children and pets; dispose of unused medication via a drug take-back program.,Contact your doctor immediately if you experience shallow breathing, difficulty waking, confusion, or signs of allergic reaction.,Do not stop abruptly; withdrawal symptoms include anxiety, sweating, diarrhea, and muscle aches.,Inform all healthcare providers that you are taking this medication.,Use exactly as directed; misuse can lead to addiction, overdose, or death.